Should I buy or sell Biodexa Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biodexa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BDRX shares. View BDRX analyst ratings or view top-rated stocks .

What is Biodexa Pharmaceuticals' stock price target for 2024?

1 brokerages have issued 12 month price objectives for Biodexa Pharmaceuticals' shares. Their BDRX share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 875.5% from the stock's current price. View analysts price targets for BDRX or view top-rated stocks among Wall Street analysts .

How have BDRX shares performed in 2024?

Biodexa Pharmaceuticals' stock was trading at $2.68 at the start of the year. Since then, BDRX shares have decreased by 69.4% and is now trading at $0.8201. View the best growth stocks for 2024 here .

Are investors shorting Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 66,800 shares, a decline of 34.9% from the March 15th total of 102,600 shares. Based on an average trading volume of 2,020,000 shares, the days-to-cover ratio is presently 0.0 days. View Biodexa Pharmaceuticals' Short Interest .

When is Biodexa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024. View our BDRX earnings forecast .

When did Biodexa Pharmaceuticals' stock split?

Shares of Biodexa Pharmaceuticals reverse split on Wednesday, July 5th 2023. The 1-80 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Biodexa Pharmaceuticals?

Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BDRX

Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free BDRX Stock Alerts

$0.82

-0.03 (-3.53%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.80
▼
$0.84
50-Day Range: $0.80
▼
$1.80
52-Week Range: $0.72
▼
$24.00

Volume: 96,353 shs
Average Volume: 1.76 million shs
Market Capitalization: $1.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Stock Analysis Analyst Forecasts Chart Competitors Financials Headlines SEC Filings Short Interest Social Media

Get Biodexa Pharmaceuticals alerts:

Biodexa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 875.5% Upside
$8.00 Price Target
Short Interest: Healthy
5.18% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.19) to ($0.13) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.79 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Biodexa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Biodexa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.18% of the outstanding shares of Biodexa Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Biodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biodexa Pharmaceuticals has recently decreased by 34.89%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Biodexa Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Biodexa Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BDRX.

0.6

News and Social Media Coverage

Search Interest
Only 5 people have searched for BDRX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
MarketBeat Follows
5 people have added Biodexa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Biodexa Pharmaceuticals are expected to grow in the coming year, from ($0.19) to ($0.13) per share.
Price to Book Value per Share Ratio
Biodexa Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

BDRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BDRX Stock News Headlines

April 3, 2024 | msn.com

7 stocks to watch on Tuesday: CHX on SLB deal, managed care players and more

April 3, 2024 | msn.com

View reaches deal with Cantor Fitzgerald and RXR to become a private company

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 2, 2024 | seekingalpha.com

Job openings roughly flat in February, with prior month's print revised down - JOLTS

April 2, 2024 | msn.com

U.S. factory orders rise more than forecast in February

March 30, 2024 | uk.investing.com

Biodexa reports promising brain cancer drug results

March 28, 2024 | finanznachrichten.de

Biodexa Pharmaceuticals Plc: Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

March 28, 2024 | benzinga.com

Gold Gains 1%; Walgreens Narrows Earnings Forecast

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 28, 2024 | msn.com

US Stocks Flat; Initial Jobless Claims Fall To 210,000

March 18, 2024 | msn.com

Biodexa Pharmaceuticals files to sell 1.28B shares for holders

March 1, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat

February 23, 2024 | finanznachrichten.de

Biodexa Pharmaceuticals PLC: Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

February 23, 2024 | globenewswire.com

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

February 9, 2024 | finanznachrichten.de

Biodexa Pharmaceuticals PLC: Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

January 22, 2024 | finanznachrichten.de

Biodexa Pharmaceuticals PLC: Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

January 22, 2024 | finance.yahoo.com

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

December 25, 2023 | uk.finance.yahoo.com

Biodexa Pharmaceuticals Plc (BDRX)

December 21, 2023 | finance.yahoo.com

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

December 19, 2023 | msn.com

Why Biodexa Pharmaceuticals (BDRX) Shares Are Getting Hammered

December 11, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday Trading

November 30, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading

November 29, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher Wednesday

November 27, 2023 | finance.yahoo.com

Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes

October 3, 2023 | finanznachrichten.de

Biodexa Pharmaceuticals PLC: Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma

September 21, 2023 | finance.yahoo.com

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)

August 15, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday's Session

See More Headlines

Receive BDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 4/26/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BDRX
CUSIP: N/A
CIK: 1643918
Web: www.midatechpharma.com
Phone: 441235888300
Fax: N/A
Employees: 27
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +875.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $870,000.00
Price / Sales: 1.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $57.76 per share
Price / Book: 0.01

Miscellaneous

Outstanding Shares: 1,290,000
Free Float: 1,283,000
Market Cap: $1.06 million
Optionable: Not Optionable
Beta: 1.49

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Stephen A. Stamp (Age 62)
CEO, CFO, Company Secretary & Director
Comp: $318.22k
Dr. Dmitry Zamoryakhin M.D. (Age 44)
Chief Scientific Officer & Chief Medical Officer
Comp: $300.99k
Dr. Daniel Palmer MBA
Ph.D., Vice President of Technology
Ms. Nicola Tuckwell
VP & Head of Clinical Operations
Ms. Fiona Sharp
Group Financial Controller

Key Competitors

View All Competitors

BDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Biodexa Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biodexa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BDRX shares.
View BDRX analyst ratings or view top-rated stocks.
What is Biodexa Pharmaceuticals' stock price target for 2024?: 1 brokerages have issued 12 month price objectives for Biodexa Pharmaceuticals' shares. Their BDRX share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 875.5% from the stock's current price.
View analysts price targets for BDRX or view top-rated stocks among Wall Street analysts.
How have BDRX shares performed in 2024?: Biodexa Pharmaceuticals' stock was trading at $2.68 at the start of the year. Since then, BDRX shares have decreased by 69.4% and is now trading at $0.8201.
View the best growth stocks for 2024 here.
Are investors shorting Biodexa Pharmaceuticals?: Biodexa Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 66,800 shares, a decline of 34.9% from the March 15th total of 102,600 shares. Based on an average trading volume of 2,020,000 shares, the days-to-cover ratio is presently 0.0 days.
View Biodexa Pharmaceuticals' Short Interest.

When is Biodexa Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our BDRX earnings forecast.
When did Biodexa Pharmaceuticals' stock split?: Shares of Biodexa Pharmaceuticals reverse split on Wednesday, July 5th 2023. The 1-80 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
How do I buy shares of Biodexa Pharmaceuticals?: Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BDRX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis

Biodexa Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX)

BDRX Stock Price History

BDRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BDRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™